A business theme involving the acquisition of exclusive rights from Eisai to research, develop and commercialize Eisai-originated ER-000582865 in China, Taiwan, Macau and Hong Kong, together with development and commercialization rights for pulmonary arterial hypertension and an option to develop it as a treatment for renal disease.